Chabbert-Buffet N, Kolanska K, Daraï E, Bouchard P
a Obstetrics and Gynecology Department , University Hospital Paris Est, Tenon APHP, University Pierre and Marie Curie , Paris , France.
b Endocrinology Unit , University Hospital Paris Est, Saint Antoine APHP, University Pierre and Marie Curie , Paris , France.
Climacteric. 2018 Aug;21(4):375-379. doi: 10.1080/13697137.2017.1386650. Epub 2018 Jan 17.
Selective progesterone receptor modulators (SPRMs) are steroid progesterone receptor ligands able to induce agonistic or antagonistic activities. Mifepristone, the class leader, was primarily used for pregnancy termination from the 1980s. Emergency contraception with extended activity was the second major development 30 years later, with mifepristone in some countries and ulipristal acetate world-wide. More recently, ulipristal acetate was released for the treatment of myoma-related uterine bleeding. In addition to a very rapid cessation of bleeding, SPRMs allow a decrease in myoma volume, as do gonadotropin releasing hormone analogs. However, estradiol secretion is not blunted by SPRMs. This offers new alternatives for myoma treatment, especially in women close to menopause. In conclusion, use of SPRMs has allowed significant progress in emergency contraception and treatment of myoma-related symptoms. Numerous future perspectives in women's health care are currently under evaluation.
选择性孕激素受体调节剂(SPRMs)是一类甾体类孕激素受体配体,能够诱导激动或拮抗活性。米非司酮作为该类药物的代表,自20世纪80年代起主要用于终止妊娠。30年后,具有延长作用的紧急避孕成为第二个主要进展,米非司酮在一些国家使用,醋酸乌利司他在全球范围内使用。最近,醋酸乌利司他被批准用于治疗子宫肌瘤相关的子宫出血。除了能非常迅速地止血外,SPRMs还能使子宫肌瘤体积缩小,促性腺激素释放激素类似物也有此作用。然而,SPRMs不会抑制雌二醇分泌。这为子宫肌瘤治疗提供了新的选择,尤其是对于接近更年期的女性。总之,SPRMs的使用在紧急避孕和子宫肌瘤相关症状的治疗方面取得了显著进展。目前,女性医疗保健领域的众多未来前景正在评估中。